Read by QxMD icon Read

Renal call cancer

Jimena Soutelo, Sofía Moldes, Cielo Frisone, Laura Salvá, Cecilia Agostinis, Gabriel Faraj
Paraneoplastic syndromes are a heterogeneous group of malignant diseases caused by events which involve endocrine, immune and metabolic aspects and whose symptoms vary according to the substance produced and the primary tumor. Hypercalcemia is a frequent complication in cancer patients. Prognosis of cancer patients with hypercalcemia is usually poor. A factor called parathyroid hormone related peptide, whose actions are similar to those of the parathyroid hormone, is thought to be the most common cause of malignancy associated hypercalcemia...
October 10, 2016: Archives of Endocrinology and Metabolism
M Bagheri, J R Speakman, F Shemirani, K Djafarian
BACKGROUND: In healthy subjects increasing BMI leads to greater mortality from a range of causes. Following onset of specific diseases, however, the reverse is often found: called the 'obesity paradox'. But we recently observed the phenomenon called the 'paradox within the paradox' for stroke patients. OBJECTIVE: The objective of our study was to examine the effect of each unit increase in BMI on renal cancer-specific survival (CSS), cancer-specific mortality (CSM), overall survival (OS) and overall mortality (OM)...
September 30, 2016: International Journal of Obesity: Journal of the International Association for the Study of Obesity
M-O Grimm
Immune checkpoint inhibitors are establishing itselves as a new systemic treatment option (in addition to chemotherapy and targeted therapy) for metastatic tumours. (Re)activating the immune system, these antibodies may lead to impressive remissions lasting for a long time in some patients. Regarding urological tumours, the anti-PD-1 antibody Nivolumab (Opdivo(®)) has been approved this year for advanced, previously treated renal cell carcinoma. In the United States, Atezolizumab (Tecentriq(®)) has been approved for metastatic urothelial carcinoma after platinum-based chemotherapy...
September 2016: Aktuelle Urologie
Jean Gabriel de Souza, Katia Lp Morais, Eduardo Anglés-Cano, Pamela Boufleur, Evandro Sobroza de Mello, Durvanei Augusto Maria, Clarice Silvia Taemi Origassa, Hamilton de Campos Zampolli, Niels Olsen Saraiva Câmara, Carolina Maria Berra, Rosemary Viola Bosch, Ana Marisa Chudzinski-Tavassi
Renal cell carcinoma (RCC), also called kidney cancer or renal adenocarcinoma, is highly resistant to current treatments. It has been previously reported that a Kunitz-type inhibitor domain-containing protein, isolated from the salivary glands of the Amblyomma cajennense tick, triggers apoptosis in murine renal adenocarcinoma cells (Renca) by inhibiting the proteasome and endoplasmic reticulum stress. Of note, Amblyomin-X is the corresponding recombinant protein identified in the cDNA library from A. cajennense salivary glands...
August 23, 2016: Oncotarget
Jia-Horng Kao, Tarik Asselah, Xiao-Guang Dou, Kamal Hamed
Hepatitis B virus (HBV) infection is one of the most serious health problems worldwide with a high risk for cirrhosis and liver cancer. Several antiviral agents have been approved for the treatment of chronic hepatitis (CHB), leading to a rapid reduction in HBV DNA and normalization of serum alanine aminotransferase (ALT) levels. Telbivudine, a potent inhibitor of HBV replication, has been shown to be well tolerated. Due to the emergence of drug resistance, optimization strategies for telbivudine therapy have been shown to improve patient responses...
August 11, 2016: Journal of Gastroenterology and Hepatology
Kwok Ying Chan, Rock Yuk Yan Leung, Ka Chi Cheung, Clarence Lam, Eleanor Koo, Sylvia Ng
OBJECTIVES: It is quite common to have advanced cancer or end-stage renal disease patients for regular or even frequent blood transfusion in palliative care. However, due to geographical reason in some hospice centers, blood transfusion is sometimes difficult if blood bank is closed during non-office hour or not available. METHODS: Here, we reported a new blood releasing system, that is, remote blood releasing system, that could be used safely by nursing staff alone when the blood bank was closed during the night time and holiday...
2016: SAGE Open Med Case Rep
Chien-Chia Huang, Wei-Lung Chen, Chien-Chin Hsu, Hung-Jung Lin, Shih-Bin Su, How-Ran Guo, Chien-Cheng Huang, Pi-Ching Chen
Backgrounds and Aim. Taiwan's population is gradually aging; however, there are no comparative data on emergency medical services (EMS) use between the elderly and nonelderly. Methods. We analyzed the emergency calls dealt with between January 1 and April 4, 2014, by EMS in one city in Taiwan. All calls were divided into two groups: elderly (≥65 years) and nonelderly (<65 years). Nontransport and transport calls were compared between the groups for demographic characteristics, transport time, reasons for calling EMS, vital signs, and emergency management...
2016: BioMed Research International
Carole Helissey, Cécile Vicier, Stéphane Champiat
Monoclonal antibodies targeting immune checkpoint molecules CTLA-4, PD-1 or PD-L1 are emerging as promising anticancer therapeutics in multiple cancer subtypes resulting in remarkable and long-lasting clinical responses. These immune checkpoint blockers (ICBs) have already obtained approval for the treatment of patients with metastatic melanoma, advanced/refractory non-small cell lung cancer and renal cell cancer. ICBs enhance immune responses against cancer cells but can also lead to inflammatory side effects called immune-related adverse events (irAEs)...
September 2016: Journal of Geriatric Oncology
H Oppel-Heuchel, M-O Grimm
Nivolumab was recently approved as the first inhibitor of the programmed death 1 (PD-1) receptor and its ligand (PD-L1) for the treatment of urological cancer, namely metastasized renal cell carcinoma after prior therapy. The use of this new immunotherapy requires special therapy monitoring and management of side effects. An increase of immune cells around the tumor can initially mimic progression (so-called pseudoprogression). Treatment-associated side effects of higher grade according to the common terminology criteria for adverse events (CTCAE grades 3 or 4) are relatively rare; however, new immune-mediated side effects can occur and affect the skin, liver (hepatitis), kidneys (nephritis), gastrointestinal tract (diarrhea and colitis), lungs (pneumonitis) and endocrine organs (hyperthyroidism, hypothyroidism and hypophysitis)...
May 2016: Der Urologe. Ausg. A
M-O Grimm, Y Winkler, I Fetter, H Oppel-Heuchel
With the advent of immune checkpoint inhibitors, immunotherapy has gained new importance in oncology. Current research is focused on the cytotoxic T‑lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) immune checkpoints. The CTLA4 antibody ipilimumab (melanoma) as well as the PD-1 antibodies nivolumab (melanoma, non-small cell lung cancer and renal cell carcinoma) and pembrolizumab (melanoma) are approved for the treatment of metastatic disease in Europe. Immune checkpoint inhibitors (re)activate the immune system against cancer cells and appear to be more effective than current standards for many tumors...
May 2016: Der Urologe. Ausg. A
R Rasenack, N Gaupp, B Rautenberg, E Stickeler, H Prömpeler
The increasing number of pregnant breast cancer patients calls for a therapy that is as efficient as possible. After 10 years of collecting data on pregnant breast cancer patients in the German Breast Group (GBG), proposals for diagnostic measures and therapy regarding this special situation have been developed on the basis of 500 observed cases. Chemotherapy is regarded as safe from the 14(th) week of gestation on, but it is strongly advised not to use trastuzumab. Adverse outcomes for the newborn were predominantly observed in cases of early preterms...
April 2016: Zeitschrift Für Geburtshilfe und Neonatologie
Jonathan Clark, Steven Wang
In many regions of the world, the most common type of parotid malignancy is metastatic malignancy. Metastatic cutaneous squamous cell carcinoma and metastatic melanoma are the most common pathologies that metastasize to the parotid gland and cervical lymph nodes. Other more rare metastatic malignancies from cutaneous primary sites include Merkel cell carcinoma, pleomorphic sarcoma (previously called malignant fibrous histiocytoma) and metastatic basal cell carcinoma. Systemic metastases can also occur from tumors such as renal cell carcinoma...
2016: Advances in Oto-rhino-laryngology
Anas Shamsi, Azaj Ahmed, Bilqees Bano
In our study renal cancer is induced in rats making use of dimethylnitrosamine (DMN). G1; Group 1 were control rats and G2; Group 2 rats were given a single intra-peritoneal injection of DMN of 50mg/kg body weight resulting in 100% incidences of renal tumors after 12 months. SEM and histopathology confirmed the presence of renal cancer in the DMN treated rats. Making use of ammonium sulphate precipitation and gel filtration chromatography on Sephacryl S-100HR column, a thiol protease inhibitor was isolated from kidney of control rats known as Rat kidney Cystatin (RKC) as well as from kidney of cancerous rat called as Cancerous Rat Kidney Cystatin (CRKC)...
March 16, 2016: Journal of Biomolecular Structure & Dynamics
Lavinia Spain, Stefan Diem, James Larkin
Immune checkpoint inhibition with the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab has improved survival in metastatic melanoma, lung cancer and renal cancer. Use of these agents holds promise in other malignancies. The augmented immune response enabled by these agents has led to a particular group of side effects called immune-related adverse events (irAEs). The main irAEs include diarrhea, colitis, hepatitis, skin toxicities and endocrinopathies such as hypophysitis and thyroid dysfunction...
March 2016: Cancer Treatment Reviews
Elinne Becket, Sameer Chopra, Christopher E Duymich, Justin J Lin, Jueng Soo You, Kurinji Pandiyan, Peter W Nichols, Kimberly D Siegmund, Jessica Charlet, Daniel J Weisenberger, Peter A Jones, Gangning Liang
Alterations in chromatin accessibility independent of DNA methylation can affect cancer-related gene expression, but are often overlooked in conventional epigenomic profiling approaches. In this study, we describe a cost-effective and computationally simple assay called AcceSssIble to simultaneously interrogate DNA methylation and chromatin accessibility alterations in primary human clear cell renal cell carcinomas (ccRCC). Our study revealed significant perturbations to the ccRCC epigenome and identified gene expression changes that were specifically attributed to the chromatin accessibility status whether or not DNA methylation was involved...
April 1, 2016: Cancer Research
Seshadri Reddy Ankireddy, Jongsung Kim
The development of chip-based, quantum dot (QD)-bead-DNA conjugate probes for hybridization detection is a prime research focus in the field of microfluidics. QD-Bead-DNA probe-based hybridization detection methods are often called "bead-based assays," and their success is substantially influenced by the dispensing and manipulation capabilities of microfluidic technology. Met was identified as a prognostic marker in different cancers including lung, renal, liver, head and neck, stomach, and breast. In this report, the cancer causing Met gene was detected with QDs attached to polystyrene microbeads...
October 2015: Journal of Nanoscience and Nanotechnology
Yunseon Jang, Jeongsu Han, Soo Jeong Kim, Jungim Kim, Min Joung Lee, Soyeon Jeong, Min Jeong Ryu, Kang-Sik Seo, Song-Yi Choi, Minho Shong, Kyu Lim, Jun Young Heo, Gi Ryang Kweon
Renal cell carcinoma (RCC) progression resulting from the uncontrolled migration and enhanced angiogenesis is an obstacle to effective therapeutic intervention. Tumor metabolism has distinctive feature called Warburg effect, which enhances the aerobic glycolysis rapidly supplying the energy for migration of tumor. To manipulate this metabolic change characteristic of aggressive tumors, we utilized the citrus extract, auraptene, known as a mitochondrial inhibitor, testing its anticancer effects against the RCC4 cell line...
November 10, 2015: Oncotarget
Eric H Kim, Seth A Strope
The American Urological Association and the National Comprehensive Cancer Network guidelines regarding postoperative surveillance for renal cell carcinoma (RCC) have provided a standardized framework for imaging following nephrectomy. These stage-stratified recommendations are based on retrospective studies that identified the timeline and location of RCC recurrences. However, the simplified and generalizable protocols offered by the American Urological Association and the National Comprehensive Cancer Network are not without limitations...
December 2015: Urologic Oncology
Paolo Malvezzi, Lionel Rostaing
INTRODUCTION: Cyclosporine-A and tacrolimus are the cornerstones in modern immunosuppression after organ transplantation. They are potent inhibitors of calcineurin, that is, so-called calcineurin-inhibitors (CNIs). However, because these drugs have narrow therapeutic windows, they are associated with many side-effects, with some being dose related. AREAS COVERED: The most frequent side-effect of CNIs is nephrotoxicity, which in the long term can contribute, to allograft deterioration...
October 2015: Expert Opinion on Drug Safety
Artem Artemov, Alexander Aliper, Michael Korzinkin, Ksenia Lezhnina, Leslie Jellen, Nikolay Zhukov, Sergey Roumiantsev, Nurshat Gaifullin, Alex Zhavoronkov, Nicolas Borisov, Anton Buzdin
A new generation of anticancer therapeutics called target drugs has quickly developed in the 21st century. These drugs are tailored to inhibit cancer cell growth, proliferation, and viability by specific interactions with one or a few target proteins. However, despite formally known molecular targets for every "target" drug, patient response to treatment remains largely individual and unpredictable. Choosing the most effective personalized treatment remains a major challenge in oncology and is still largely trial and error...
October 6, 2015: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"